ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

MEPSEVII
Inborn errors of metabolism
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

MEPSEVII Rx

Generic Name and Formulations:
Vestronidase alfa-vjbk 2mg/mL; soln for IV infusion after dilution; preservative-free.

Company:
Ultragenyx Pharmaceutical Inc.

Therapeutic Use:

Indications for MEPSEVII:

Treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).

Limitations Of use:

Effect on the CNS manifestations of MPS VII has not been determined.

Adults and Children:

Premedicate with a non-sedating antihistamine with or without an antipyretic 30–60mins prior to infusion. Give as IV infusion over 4hrs (infuse first 2.5% of total volume over 1hr, then increase rate as tolerated over next 3hrs); see full labeling. 4mg/kg every 2 weeks.

Boxed Warning:

Anaphylaxis.

Warnings/Precautions:

Have appropriate medical support readily available. Should be administered under supervision of healthcare professional. Monitor during and for ≥60mins post-infusion for anaphylaxis; discontinue immediately if a severe systemic reaction occurs. Elderly. Pregnancy. Nursing mothers.

Pharmacological Class:

Recombinant human lysosomal beta glucuronidase.

Adverse Reactions:

Infusion site extravasation, diarrhea, rash, anaphylaxis, infusion site swelling, peripheral swelling, pruritus.

Generic Availability:

NO

How Supplied:

Single-dose vial (5mL)—1

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs